Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3- dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission

Molecular Pharmacology

Volumn 70, Issue 3, 2006, Pages 1022-1032

  Frizelle, Pamela A ^a   Chen, Philip E ^a   Wyllie, David J A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[1 (4 BROMO PHENYL) ETHYLAMINO] (2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YL) METHYL] PHOSPHONIC ACID; ALANINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NVPAAM 077; RECOMBINANT RECEPTOR; THREONINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG POTENCY; EQUILIBRIUM CONSTANT; LIGAND BINDING; NONHUMAN; OOCYTE; POINT MUTATION; PRIORITY JOURNAL; RAT; STEADY STATE; SYNAPTIC TRANSMISSION; XENOPUS LAEVIS;

AMINO ACID SEQUENCE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; EXCITATORY POSTSYNAPTIC POTENTIALS; KINETICS; MOLECULAR SEQUENCE DATA; OOCYTES; POINT MUTATION; QUINOXALINES; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; SYNAPTIC TRANSMISSION; XENOPUS LAEVIS;

EID: 33747598487     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.024042     Document Type: Article

References (41)

1. Anson LC, Chen PE, Wyllie DJA, Colquhoun D, and Schoepfer R (1998) Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors. J Neurosci 18:581-589.
2. Anson LC, Schoepfer R, Colquhoun D, and Wyllie DJA (2000) Single-channel analysis of an NMDA receptor possessing a mutation in the region of the glutamate binding site. J Physiol (Lond) 527:225-237.
3. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48-57.
4. Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, and Schmutz M (2002) 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg Med Chem Lett 12:1099-1102.
5. Banke TG and Traynelis SF (2003) Activation of NR1/NR2B NMDA receptors. Nat Neurosci 6:144-152.
6. Barker GR, Warburton EC, Koder T, Dolman NP, More JC, Aggleton JP, Bashir ZI, Auberson YP, Jane DE, and Brown MW (2006) The different effects on recognition memory of perirhinal kainate and NMDA glutamate receptor antagonism: implications for underlying plasticity mechanisms. J Neurosci 26:3561-3566.
7. Benveniste M and Mayer ML (1991) Structure-activity analysis of binding kinetics for NMDA receptor competitive antagonists: the influence of conformational restriction. Br J Pharmacol 104:207-221.
8. Benveniste M, Mienville JM, Sernagor E, and Mayer ML (1990) Concentration-jump experiments with NMDA antagonists in mouse cultured hippocampal neurons. J Neurophysiol 63:1373-1384.
9. Berberich S, Punnakkal P, Jensen V, Pawlak V, Seeburg PH, Hvalby O, and Kohr G (2005) Lack of NMDA receptor subtype selectivity for hippocampal long-term potentiation. J Neurosci 25:6907-6910.
10. Chen PE, Geballe MT, Stansfeld PJ, Johnston AR, Yuan H, Jacob AL, Snyder JP, Traynelis SF, and Wyllie DJA (2005) Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol 67:1470-1484.
11. Chen PE, Johnston AR, Mok MH, Schoepfer R, and Wyllie DJA (2004) Influence of a threonine residue in the S2 ligand binding domain in determining agonist potency and deactivation rate of recombinant NR1/NR2D NMDA receptors. J Physiol (Lond) 558:45-58.
12. Chen PE and Wyllie DJA (2006) Pharmacological insights obtained from structure-function studies of ionotropic glutamate receptors. Br J Pharmacol 147:839-853.
13. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
14. Dingledine R, Borges K, Bowie D, and Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7-61.
15. Erreger K, Chen PE, Wyllie DJA, and Traynelis SF (2004) Glutamate receptor gating. Crit Rev Neurobiol 16:187-224.
16. Erreger K, Dravid SM, Banke TG, Wyllie DJA, and Traynelis SF (2005a) Subunitspecific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signaling profiles. J Physiol (Lond) 563:345-358.
17. Erreger K, Geballe MT, Dravid SM, Snyder JP, Wyllie DJA, and Traynelis SF (2005b) Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J Neurosci 25:7858-7866.
18. Feng B, Tse HW, Skifter DA, Morley R, Jane DE, and Monaghan DT (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol 141:508-516.
19. Fischer G, Mutel V, Trube G, Malherbe P, Kew JNC, Mohacsi E, Heitz MP, and Kemp JA (1997) Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283:1285-1292.
20. Furukawa H, Singh SK, Mancussco R, and Gouaux E (2005) Subunit arrangement of and function in NMDA receptors. Nature (Lond) 438:185-192.
21. Hess SD, Daggett LP, Crona J, Deal C, Lu CC, Urrutia A, Chavez-Noriega L, Ellis SB, Johnson EC, and Velicelebi G (1996) Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 278:808-816.
22. Ishii T, Moriyoshi K, Sugihara H, Sakurada K, Kadotani H, Yokoi M, Akazawa C, Shigemoto R, Mizuno N, Masu M, et al. (1993) Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J Biol Chem 268:2836-2843
23. Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, and Behrens MM (2006) A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 26:1604-1615.
24. Laube B, Hirai H, Sturgess M, Betz H, and Kuhse J (1997) Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 18:493-503.
25. Laube B, Schemm R, and Betz H (2004) Molecular determinants of ligand discrimination in the glutamate-binding pocket of the NMDA receptor. Neuropharmacology 47:994-1007.
26. Li S, Tian X, Hartley DM, and Feig LA (2006) Distinct roles for Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and Ras-GRF2 in the induction of long-term potentiation and long-term depression. J Neurosci 26:1721-1729.
27. Liu L, Wong TP Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, and Wang YT (2004) Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science (Wash DC) 304:1021-1024.
28. Mallon AP, Auberson YP, and Stone TW (2005) Selective subunit antagonists suggest an inhibitory relationship between NR2B and NR2A-subunit containing N-methyl-D-aspartate receptors in hippocampal slices. Exp Brain Res 162:374-383.
29. Massey PV, Johnson BE, Moult PR, Auberson YP, Brown MW, Molnar E, Collingridge GL, and Bashir ZI (2004) Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci 24:7821-7828.
30. Monyer H, Burnashev N, Laurie DJ, Sakmann B, and Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540.
31. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, and Seeburg PH (1992) Heteromeric NMDA receptors: molecular and functional distinctions of subtypes. Science (Wash DC) 256:1217-1221.
32. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, Traynelis SF, and Dingledine R (1998) Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1:659-667.
33. Neyton J and Paoletti P (2006) Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci 26:1331-1333.
34. Priestley T, Laughton P, Myers J, Le Bourdelles B, Kerby J, and Whiting PJ (1995) Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. Mol Pharmacol 48:841-848.
35. Toyoda H, Zhao MG, and Zhuo M (2005) Roles of NMDA receptor NR2A and NR2B subtypes for long-term depression in the anterior cingulate cortex. Eur J Neurosci 22:485-494.
36. Varney MA, Jachec C, Deal C, Hess SD, Daggett LP, Skvoretz R, Urcan M, Morrison JH, Moran T, Johnson EC, et al. (1996) Stable expression and characterization of recombinant human heteromeric N-methyl-D-aspartate receptor subtypes NMDAR1A/2A and NMDAR1A/2B in mammalian cells. J Pharmacol Exp Ther 279:367-378.
37. Vicini S, Wang JF, Li JH, Zhu WJ, Wang YH, Luo JH, Wolfe BB, and Grayson DR (1998) Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. J Neurophysiol 79:555-566.
38. Weitlauf C, Honse Y, Auberson YP, Mishina M, Lovinger DM, and Winder DG (2005) Activation of NR2A-containing NMDA receptors is not obligatory for NMDA receptor-dependent long-term potentiation. J Neurosci 25:8386-8390.
39. Williams K (1993) Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44:851-859.
40. Wyllie DJA, Béhé P, and Colquhoun D (1998) Single-channel activations and concentration jumps: comparison of recombinant NR1a/NR2A and NR1a/NR2D NMDA receptors. J Physiol (Lond) 510:1-18.
41. Wyllie DJA, Johnston AR, Lipscombe D, and Chen PE (2006) Single-channel analysis of a point mutation of a conserved serine residue in the S2 ligand binding domain of the NR2A NMDA receptor subunit. J Physiol (Lond) 574:477-489.